Abstracts Archive - Page 1491 of 1683 - ATC Abstracts

2015 American Transplant Congress
A 52-Week, Multicenter, Prospective, Observational, Non-Interventional, Open-Label Study to Assess the Effectiveness, Safety and Tolerability of Everolimus in Kidney Transplant Patients in Taiwan
S.-M. Wang,¹ P.-C. Lee,² J.-D. Lian,³ K.-H. Shu,⁴ S.-T. Wu,⁵ H.-C. Chen,⁶ C.-C. Huang,⁷ M.-S. Wu,⁸ Y.-C. Tian,⁹ Y.-J. Chiang,¹⁰ Y.-T. Chen,¹¹ H.-P. Wang.¹²
¹National Taiwan University Hospital, Taipei, Taiwan; ²National Cheng Kung University Hospital, Tainan, Taiwan; ³Chung Shan Medical University Hospital, Taichung, Taiwan; ⁴Taichung Veteran's General Hospital, Taichung, Taiwan; ⁵TriService General Hospital, Taipei, Taiwan; ⁶Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; ⁷China Medical University Hospital, Taichung, Taiwan; ⁸Taipei Medical University Hospital, Taipei, Taiwan; ⁹ChangGung Memorial Hospital–Taipei, Taipei, Taiwan; ¹⁰ChangGung Memorial Hospital–LinKou, Taoyuan, Taiwan; ¹¹ChangGung Memorial Hospital-Kaohsiung, Kaohsiung, Taiwan; ¹²E-Da Hospital, Kaohsiung, Taiwan.
The study aimed to assess the clinical safety and tolerability of everolimus (EVR) in Taiwan kidney transplant patients.This study enrolled 203 kidney transplant recipients, between…
2015 American Transplant Congress
Safety and Efficacy of Low Dose and Very Low Dose Extended-Release Tacrolimus / MMF in De Novo Kidney Transplant Recipients
Y. Watarai,¹ M. Okada,¹ K. Futamura,¹ K. Ito,¹ T. Yamamoto,¹ M. Tsujita,¹ T. Hiramitsu,¹ N. Goto,¹ S. Narumi,¹ T. Kobayashi.²
¹Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan; ²Applied Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Recently, once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well evaluated. We have validated low dose…
2015 American Transplant Congress
Outcomes of Kidney Transplant Recipients Minimally Immunosuppressed: A Cohort Study Analysis
A.-H. Querard,^1,2,3 F. Gillaizeau,^2,1 G. Couvrat-Desvergne,^1,2,3 J. Dantal,^1,4,5 P. Daguin,¹ S. Le Floch,¹ S. Castagnet,⁶ S. Brouard,^1,4 Y. Foucher,^2,1 M. Giral.^1,2,4,5
¹Institute for Transplantation, Urology and Nephrology (ITUN), CHU Nantes, RTRS « Centaure », INSERM U1064, Université de Nantes, Nantes, France; ²EA 4275 SPHERE– Biostatistics, Pharmacoepidemiology and Human Sciences Research, Nantes University, Nantes, France; ³Centre Hospitalier Departemental de Vendée, La Roche sur Yon, France; ⁴Centre d'Investigation Clinique Biothérapie, Nantes, France; ⁵Centre Hospitalier Universitaire, Nantes, France; ⁶HLA Laboratory, Etablissement Français du Sang, Nantes, France.
Background: Renal transplantation is the treatment of choice for endstage renal disease. Nevertheless, it involves immunosuppressive treatments with Serious Adverse Events (SAE) such as infections…
2015 American Transplant Congress
Reduction of Tacrolimus With Everolimus Addition in Maintenance Immunosuppression Improves Calcineurin Inhibitor-Induced Arteriolopathy in Kidney Allografts
M. Miura,¹ H. Higashiyama,¹ Y. Fukasawa.²
¹Department of Renal Transplant Surgery, Sapporo Hokuyu Hospital, Sapporo, Japan; ²Department of Pathology, Sapporo City General Hospital, Sapporo, Japan.
Objectives: Although conversion of calcineurin inhibitor (CNI)-based immunosuppression to everolimus (EVR) has been shown to improve graft function, no histopathological evidence has been reported. The…
2015 American Transplant Congress
Calcineurin Inhibitor-Free Immunossupresion After Kidney Transplantation, Using Everolimus De Novo – Single Center Experience
M. Stronka, Z. Adamska, L. Cichanska, J. Kubiak, M. Gamrat, M. Karczewski.
Department of Transplantology, General, Vascular and Plastic Surgery, Clinical Hospital of Poznan University of Medical Sciences, Poznan, Poland.
The aim of the study was to analyse the clinical outcome in kidney transplant recipients treated with CNI (calcineurin inhibitors)-free protocol versus kidney transplant recipients…
2015 American Transplant Congress
12-Month Athena Study: Everolimus Vs. Standard Regimen in De Novo Renal Transplant Recipients
C. Sommerer,¹ B. Suwelack,¹ D. Dragun,¹ I. Hauser,¹ P. Schenker,¹ D. Bäumer,² B. Nashan,¹ F. Thaiss.¹
¹Athena Study Group, Germany; ²Novartis, Pharma, Germany.
Background: Post-kidney transplant (KTx) long-term and full dose/standard calcineurin inhibitor (CNI) use is associated with an increased risk for malignancies, cardiovascular disease, and renal failure.…
2015 American Transplant Congress
Pharmacokinetics of Mycophenolic Acid (MPA) in Elderly Compared to Young Recipients in the First Year After Renal Transplantation. Data from the NEverOLd Trial
P. Romano,¹ F. Agena,² P. Ebner,¹ A. Triboni,² F. Ramos,² N. Galante,² F. Lemos,² N. Sumita,¹ E. David-Neto.²
¹Division of Central Laboratory, – Hospital das Clinicas – University of São Paulo School of Medicine, Sao Paulo, Brazil; ²Renal Transplantation Service, – Hospital das Clinicas – University of São Paulo School of Medicine, Sao Paulo, Brazil.
Elderly (≥60years) recipients are nowadays receiving renal transplants more frequently. The pharmacokinetics studies (PK) of immunosuppressive drugs in healthy volunteers, rarely, if ever, include old…
2015 American Transplant Congress
Post Hoc Subgroup Analysis of ZEUS: Outcome on Renal Function, Efficacy and Safety in Living-Donor Kidney Transplant Recipients After Conversion from a Calcineurin Inhibitor to an Everolimus Based Regimen: 5 Year Follow-Up Data
F. Lehner,¹ K. Budde,¹ R. Wuethrich,² P. Reinke,¹ W. Arns,¹ A. Muehlfeld,¹ U. Eisenberger,¹ R. Stahl,¹ K. Heller,¹ O. Witzke,¹ B. Suwelack,¹ H. Wolters,¹ I. Hauser,¹ M. Porstner,³ C. Sommerer.¹
¹ZEUS Study Group, Germany; ²ZEUS Study Group, Switzerland; ³Novartis, Pharma, Germany.
Background: To study renal function and patient outcome after 5 years in living donation subgroup of kidney de novo transplant recipients after conversion to an…
2015 American Transplant Congress
Intra-Lymphocyte Concentrations of Mycophenolic Acid Correlate With the Incidence of Early Graft Rejection in Renal Transplant Recipients
Z. Md Dom,² J. Coller,² R. Carroll,³ A. Somogyi,² B. Sallustio.¹
¹Clinical Pharmacology, The Queen Elizabeth Hospital, Adelaide, Australia; ²Discipline of Pharmacology, Univeristy of Adelaide, Adelaide, Australia; ³Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia.
Introduction: Although routine therapeutic drug monitoring of mycophenolic acid (MPA) concentrations in plasma has been recommended to individualize MPA doses in transplant recipients, little is…
2015 American Transplant Congress
Mycophenolate Dose Reductions Contribute to Suboptimal Graft Outcomes in Kidney Transplant Recipients
K. Boyle, J. Fleming, D. Taber, K. Covert, J. Casale, C. Staino, N. Pilch, C. Mardis, H. Meadows, T. Srinivas, J. McGillicuddy, K. Chavin, C. Bratton, P. Baliga.
Medical University of South Carolina, Charleston, SC.
The purpose of this study was to analyze outcomes in patients with mycophenolate mofetil (MMF) dose reductions below doses proven to prevent rejection in a…